Platform for Delivering Therapeutic Proteins into the Cytosol
Details about this service are coming soon!

Stay tuned for more information.

Intracellular Protein Therapeutics (IPT)

Platform for Delivering Therapeutic Proteins into the Cytosol

There is a pressing need for methods delivering therapeutic macromolecules to their intracellular targets at low nanomolar concentrations without endosomal entrapment. Certain viruses and bacterial toxins exploit lipid raft-mediated endocytosis to deliver macromolecules in their functional form without degradation, which we set out to mimic in our approach. These proteins of viral and bacterial origins trigger the desired intracellular delivery by binding to gangliosides at the lipid raft entry points.

We discovered a pentapeptide sequence that specifically captures the lipid raft marker ganglioside GM1. Thus, it triggers endocytosis on various human live cell lines. The cargo-loaded endosomes show limited fusion with lysosomes. Several immunoglobulin G complexes were successfully delivered into live cells at extracellular concentrations ranging from 20 to 160 nM. The antibodies’ molecular recognition regions remained functional, and the escape of the functional cargo protein to the cytosol was observed without any additional endosomal escape sequence. The carrier tag was not toxic even in the high micromolar region.

Unique Solution

Our receptor-based approach is a promising alternative intracellular delivery method with the following unique combination of advantageous properties.

Cytosolic internalization is achievable at the antibody concentration levels normally applied in antibody therapy (ca. 100 nM in serum)

The intracellular distribition can be controlled by the target recognition properties of the cargo protein/antibody.

The sequence is very short, which minimize the unwanted interference with the cargo protein.

The non-toxic signal tag triggers the advantageous lipid raft-mediated endocytosis, which facilitates the endosomal escape.

The a-peptidic sequence can be readily fused to proteins in a cell line development pipeline

XPAMAC is a Key Enabling Technology for Intracellular Application of Protein Therapeutics without Chemical Modification of the Cargo

Advantages of the technology

The pentapeptide tag (tag) is the smallest nanomolar endocytosis signal with minimal interference with the cargo

The tag breaks the carrier-cargo cooptimization paradigm, it internalized a number of antibodies and other proteins efficiently

Fast cell line development process within 8 weeks for a tag-fused product with the XPAMAC technology

Candidate protein therapeutics can be rapidly tested for the intracellular effects with chemical tagging before the specific cell line development of the fused carrier-cargo product

Low-cost and accelerated screening of protein candidates

Potentially applicable for nucleic acid therapeutics w/o lipid nanocapsules with the appropriate linker chemistry

IP Protection

The patent for the tag-triggered cytosolic delivery of macromolecules has been filed. The IP protection process is in progress with the EU and US patent offices. We are continuously developing other coupled patent applications to further secure our technology, ensuring well-protected investment.